1
|
Önder T, Ateş Ö, Öner I, Karaçin C. Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study. Int J Clin Oncol 2024:10.1007/s10147-024-02528-w. [PMID: 38687407 DOI: 10.1007/s10147-024-02528-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Accepted: 04/04/2024] [Indexed: 05/02/2024]
Abstract
AIMS AND OBJECTIVES Human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) is a new entity considered a biologically distinct subtype from HER2-zero BC. However, the importance of HER2 low expression on the activity of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) remains unclear. METHODS/MATERIALS We conducted a single-center retrospective study including hormone receptor-positive (HR +) /HER2- metastatic BC (mBC) patients treated with CDK4/6i plus endocrine treatment (ET) as first-line therapy. Clinical outcomes were analyzed according to HER2 expression. RESULTS 258 women were analyzed with a median follow-up of 25.4 months; 39.9% had HER2 low, and 60.1% had HER2 zero BC. Median progression-free survival (mPFS) in the HER2-low group was 27.6 months compared with 44.3 months in the HER2-zero group (p = 0.341). In patients receiving ribociclib, the mPFS in the HER2-low group was 24.2 months compared with 53.1 months in the HER2-zero group (multivariate-adjusted HR: 1.981, 95 Cl 1.094-3.586; p = 0.024). The survival probabilities at 24, 36 and 48 months for the HER2 low and HER2 zero groups were 82%, 69%, 69% and 83%, 75% and 69%, respectively (p = 0.336). Objective response rate (p = 0.179) and disease control rate (p = 0.338) did not significantly differ between HER-2-low and HER-2-zero groups. CONCLUSIONS The mPFS in the Her2-zero group was almost twice that of the Her2-low group, but the difference was not statistically significant. mPFS was significantly longer in the HER2-zero group compared to the HER2-low group in patients receiving ribociclib. More prospective studies are needed to understand the actual consequences of this biomarker.
Collapse
Affiliation(s)
- T Önder
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
| | - Ö Ateş
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - I Öner
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - C Karaçin
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| |
Collapse
|
2
|
Türkel A, Doğan M, Sertesen E, Karaçin C, Irkkan SÇ, Ateş Ö. Prognostic factors in non-metastatic HER2 'low' and HER2 'negative' breast cancer: single institute experience. Wien Klin Wochenschr 2024:10.1007/s00508-023-02315-z. [PMID: 38180508 DOI: 10.1007/s00508-023-02315-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Accepted: 12/01/2023] [Indexed: 01/06/2024]
Abstract
AIM Comparison of prognosis and survival in human epidermal growth factor receptor 2 (HER2)-low and HER2-negative patients with early stage or locally advanced, hormone receptor-positive breast cancer. MATERIAL AND METHODS In a retrospective single center study, the patients with early stage or locally advanced stage, hormone receptor (HR)-positive [estrogen receptor (ER) ≥ 1% and/or progesterone receptor (PR) ≥ 1%] and HER2 negative or HER2 low invasive breast cancer diagnosis were included. A total of 444 patients were included in the study. Patients were divided into two groups: HER2 negative and HER2 low. There were 235 (53%) patients in the HER2 negative group and 209 (47%) patients in the HER2 low group. RESULTS The HER2 low group had significantly longer 5‑year disease-free survival (DFS) than the HER2 negative group. The patients with lower Ki67 (< 20%) also had a longer 5‑year DFS. CONCLUSION Nonmetastatic HR+/HER2 low breast cancer patients had better DFS than HR+/HER2 negative ones. The Ki67 level and HER2 low status were independent prognostic factors. Randomized clinical trials are needed in early stage HER2 low breast cancer patients.
Collapse
Affiliation(s)
- Alper Türkel
- Division of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey.
- , Vatan Street No: 91, 06200, Yenimahalle/Ankara, Turkey.
| | - Mutlu Doğan
- Division of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Elif Sertesen
- Division of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Cengiz Karaçin
- Division of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Sultan Çiğdem Irkkan
- Division of Pathology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Öztürk Ateş
- Division of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| |
Collapse
|
3
|
Erdem HB, Alay MT, Özdemir Z, Çevik E, Ateş Ö, Karaçin C, Şahin İ, Doğan M, Bahsi T. Higher TP53 somatic mutation prevalence from liquid biopsy analysis in ever smoker non-small-cell lung cancer patients. Mutat Res 2024; 828:111847. [PMID: 38071953 DOI: 10.1016/j.mrfmmm.2023.111847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Revised: 10/20/2023] [Accepted: 11/23/2023] [Indexed: 05/20/2024]
Abstract
OBJECTIVE Cigarette smoking is a primary risk factor, linked to 80% of LC deaths. TP53, a key gene, is implicated in various cancers, with TP53 alterations in 36.7% of cancers. This research aims to investigate TP53 mutations detected in NSCLC patients by liquid biopsy and explore the relationship between these mutations and smoking history. MATERIAL AND METHOD The study enrolled a total of 340 patients diagnosed with non-small cell lung cancer (NSCLC). For sequencing, the Illumina NextSeq 500 system was utilized. The oncogenicity of the variants was assessed according to the ClinGen/CGC/VICC SOP and the variants were categorized into four tiers according to AMP/ASCO/CAP. RESULTS The most common mutations were in TP53 (48.7%), followed by EGFR, PIK3CA, and PTEN. Missense mutations were frequent, with TP53 and EGFR having higher rates in ever-smokers. No indels or complex mutations were found in ever-smokers. Patient age ranged from 20 to 86 years. Tier I-II variants were more common in ever-smokers, while Tier III variants were prevalent in never-smokers. TP53 mutations were more frequent in ever-smokers, showing a strong association with smoking. Domain distribution showed differences in PIK3CA. Transversion/transition ratios varied by gene and smoking status. DISCUSSION The presence of TP53 mutations is strongly associated with both cigarette smoking and elevated Tv/Ti ratios. The tier status of TP53, EGFR, and PTEN variants does not show a specific domain distribution, but interesting associations are observed between the tier status and domain distribution in PIK3CA variants. Therefore, further comprehensive investigations are needed to explore this entity, as well as the underlying factors contributing to the increased Tv/Ti rates in the TP53 gene. Such research will provide deeper insights into the genetic alterations associated with smoking and tumor heterogeneity, ultimately aiding in the development of targeted therapies.
Collapse
Affiliation(s)
- Haktan Bağış Erdem
- Ankara Etlik City Hospital, Department of Medical Genetics, Ankara, Türkiye; University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Medical Genetics, Ankara, Türkiye.
| | - Mustafa Tarık Alay
- Ankara Etlik City Hospital, Department of Medical Genetics, Ankara, Türkiye
| | - Zeynep Özdemir
- Ankara Etlik City Hospital, Department of Medical Genetics, Ankara, Türkiye
| | - Ezgi Çevik
- Ankara Etlik City Hospital, Department of Medical Genetics, Ankara, Türkiye
| | - Öztürk Ateş
- University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Türkiye
| | - Cengiz Karaçin
- University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Türkiye
| | - İbrahim Şahin
- Arabian Gulf University Medical Faculty, Department of Medical Genetics, Manama, Bahrain
| | - Mutlu Doğan
- University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Türkiye
| | - Taha Bahsi
- Ankara Etlik City Hospital, Department of Medical Genetics, Ankara, Türkiye
| |
Collapse
|
4
|
Özdemir Z, Çevik E, Öksüzoğlu ÖBÇ, Doğan M, Ateş Ö, Esin E, Bilgetekin İ, Demirci U, Köseoğlu Ç, Topal A, Karadurmuş N, Erdem HB, Bahsi T. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling. Mutat Res 2023; 827:111831. [PMID: 37453313 DOI: 10.1016/j.mrfmmm.2023.111831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2023] [Revised: 06/08/2023] [Accepted: 07/01/2023] [Indexed: 07/18/2023]
Abstract
OBJECTIVE Hereditary cancer syndromes constitute 5-10% of all cancers. The development of next-generation sequencing technologies has made it possible to examine many hereditary cancer syndrome-causing genes in a single panel. This study's goal was to describe the prevalence and the variant spectrum using NGS in individuals who were thought to have a hereditary predisposition for cancer. MATERIAL AND METHOD Analysis was performed for 1254 who were thought to have a familial predisposition for cancer. We excluded 46 patients who were carrying BRCA1/2 variants in this study, for focusing on the rare gene mutations. Sequencing was performed using the Sophia Hereditary Cancer Solution v1.1 Panel and the Qiagen Large Hereditary Cancer Panel. The Illumina MiSeq system was used for the sequencing procedure. The software used for the data analyses was Sophia DDM and QIAGEN Clinical Insight (QCITM) Analyze. The resulting genomic changes were classified according to the current guidelines of ACMG/AMP. RESULTS Pathogenic/likely pathogenic variants were detected in 172 (13.7%) of 1254 patients. After excluding the 46 BRCA1/2-positive patients, among the remaining 126 patients; there were 60 (4.8%) breast cancer, 33 (2.6%) colorectal cancer, 9 (0.7%) ovarian cancer, 5 (0.4%) endometrium cancer, 5 (0.4%) stomach cancer, 3 (0.2%) prostate cancer patients. The most altered genes were MUTYH in 27 (2.1%) patients, MMR genes (MLH1, MSH6, MSH, MSH2, PMS2 and EPCAM) in 26 (2%) patients, and ATM in 25 (2%) patients. We also examined the genotype-phenotype correlation in rare variants. Additionally, we identified 11 novel variations. CONCLUSION This study provided significant information regarding rare variants observed in the Turkish population because it was carried out with a large patient group. Personalized treatment options and genetic counseling for the patients are therefore made facilitated.
Collapse
Affiliation(s)
- Zeynep Özdemir
- Ankara Etlik City Hospital, Department of Medical Genetics, Ankara, Turkiye.
| | - Ezgi Çevik
- Ankara Etlik City Hospital, Department of Medical Genetics, Ankara, Turkiye
| | | | - Mutlu Doğan
- University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Turkiye
| | - Öztürk Ateş
- University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Turkiye
| | - Ece Esin
- Bayındır Hospital, Department of Medical Oncology, Ankara, Turkiye
| | - İrem Bilgetekin
- Lösante Hospital, Department of Medical Oncology, Ankara, Türkiye
| | - Umut Demirci
- Memorial Hospital, Department of Medical Oncology, Ankara, Turkiye
| | - Çağlar Köseoğlu
- University of Health Sciences, Gülhane Training and Research Hospital, Department of Medical Oncology, Ankara, Turkiye
| | - Alper Topal
- University of Health Sciences, Gülhane Training and Research Hospital, Department of Medical Oncology, Ankara, Turkiye
| | - Nuri Karadurmuş
- University of Health Sciences, Gülhane Training and Research Hospital, Department of Medical Oncology, Ankara, Turkiye
| | - Haktan Bağış Erdem
- Ankara Etlik City Hospital, Department of Medical Genetics, Ankara, Turkiye
| | - Taha Bahsi
- Ankara Etlik City Hospital, Department of Medical Genetics, Ankara, Turkiye
| |
Collapse
|
5
|
Türkel A, Özdoğan S, Yekedüz E, Şeyran E, Karaçin C, Ateş Ö. Vortex keratopathy associated with ribociclib. J Oncol Pharm Pract 2023; 29:230-232. [PMID: 35570741 DOI: 10.1177/10781552221101799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are the new generation drugs that have been started to be used in our clinical practice recently. These drugs have been shown to have better progression-free survival compared to standard therapy in patients with hormone receptor-positive (HR) and human epidermal growth factor receptor 2 (HER-2)-negative breast cancer. The most common side effects of CDK 4-6 inhibitors are neutropenia, nausea, leukopenia, fatigue, and diarrhea. This case demonstrated vortex keratopathy in both eyes, a rare condition in patients with breast cancer treated with ribociclib. CASE REPORT A 68-year-old female patient was diagnosed with locally advanced HR (+)/HER2 (-) breast cancer in March 2015. In June 2021, bone metastases were detected. The patient was started on ribociclib and fulvestrant. After three cycles of ribociclib and fulvestrant treatment, she was admitted with the complaint of blurred vision in her left eye. Slit-lamp biomicroscopy examination revealed subepithelial haze with central subepithelial whorls in both corneas, more in the left eye, and also a mild punctate epithelial staining was observed with the application of fluorescein dye. MANAGEMENT AND OUTCOME Ribociclib treatment was immediately discontinued and no changes were observed in the cornea and vision levels during the one-month follow-up. DISCUSSION Routine and regular follow-up eye examinations in breast cancer patients treated with ribociclib may benefit patients in our daily clinical practice and may help us to detect side effects at an early stage and to manage them more effectively.
Collapse
Affiliation(s)
- Alper Türkel
- Division of Medical Oncology, 146995Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Sibel Özdoğan
- Division of Ophthalmology, 146995Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Emre Yekedüz
- Division of Medical Oncology, 146995Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Erdoğan Şeyran
- Division of Medical Oncology, 146995Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Cengiz Karaçin
- Division of Medical Oncology, 146995Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Öztürk Ateş
- Division of Medical Oncology, 146995Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| |
Collapse
|
6
|
Alkan A, Yaşar A, Güç ZG, Gürbüz M, Başoğlu T, Sezgin Göksu S, Buğdaycı Başal F, Türk HM, Özdemir Ö, Yeşil Çınkır H, Güven DC, Kuş T, Türker S, Koral L, Karakaş Y, Ak N, Paydaş S, Karcı E, Demiray AG, Demir A, Alan Ö, Keskin Ö, Nayır E, Tanrıverdi Ö, Yavuzşen T, Yumuk PF, Ateş Ö, Coşkun HŞ, Turhal S, Çay Şenler F. Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). Eur J Cancer Care (Engl) 2020; 29:e13296. [PMID: 32864838 DOI: 10.1111/ecc.13296] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Revised: 07/16/2020] [Accepted: 08/07/2020] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Fear of cancer recurrence (FCR) is an important psychological trauma associated with reduction in the quality of life, disruptions in the level of adjustment, emotional distress and anxiety. The purpose of the study was to evaluate the impact of patient-physician relationship on FCR. METHODS The study was designed as a multicentre survey study. The cancer survivors, who were under remission, were evaluated with structured questionnaires. Patient-physician relationship (PPR) scale in which higher scores indicate better relationship and FCR inventory was used. RESULTS Between January and April 2019, 1,580 patients were evaluated. The median age was 57.0 (19-88), and 66% were female. There was high level of FCR scores in 51% of participants. There was a negative correlation between PPR and FCR scores (r = -.134, p < .001). In multivariate analysis, young age, female gender, history of metastasectomy and worse PPR were associated with high levels of FCR. CONCLUSION It is the first data showing the adverse impact of worse PPR on FCR. The strategies to improve the PPR should be practised. In addition, the cancer survivors, who are under the risk of FCR, should be evaluated and managed.
Collapse
Affiliation(s)
- Ali Alkan
- Medical Oncology, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey
| | - Arzu Yaşar
- Medical Oncology, Ankara University School of Medicine, Ankara, Turkey
| | - Zeynep Gülsüm Güç
- Medical Oncology, Dokuz Eylül University School of Medicine, İzmir, Turkey
| | - Mustafa Gürbüz
- Medical Oncology, Ankara University School of Medicine, Ankara, Turkey
| | - Tuğba Başoğlu
- Medical Oncology, Marmara University School of Medicine, İstanbul, Turkey
| | - Sema Sezgin Göksu
- Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Fatma Buğdaycı Başal
- Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Hacı Mehmet Türk
- Medical Oncology, Bezmialem Vakıf University School of Medicine, İstanbul, Turkey
| | - Özlem Özdemir
- Medical Oncology, İzmir Bozyaka Research and Training Hospital, İzmir, Turkey
| | - Havva Yeşil Çınkır
- Medical Oncology, Gaziantep University School of Medicine, Gaziantep, Turkey
| | - Deniz Can Güven
- Medical Oncology, Hacettepe University School of Medicine, Ankara, Turkey
| | - Tülay Kuş
- Medical Oncology, Dr Ersin Arslan Training and Research Hospital, Gaziantep, Turkey
| | - Sema Türker
- Medical Oncology, Dışkapı Yıldırım Beyazıt Research and Training Hospital, Ankara, Turkey
| | - Lokman Koral
- Medical Oncology, Çanakkale Onsekiz Mart University School of Medicine, Çanakkale, Turkey
| | - Yusuf Karakaş
- Medical Oncology, Bodrum Acıbadem Hospital, Muğla, Turkey
| | - Naziye Ak
- Department of Medical Oncology, Institute of Oncology, Istanbul University, İstanbul, Turkey
| | - Semra Paydaş
- Medical Oncology, Çukurova University School of Medicine, Adana, Turkey
| | - Ebru Karcı
- Medical Oncology, Bağcılar Research and Training Hospital, İstanbul, Turkey
| | | | - Atakan Demir
- Medical Oncology, Acıbadem Maslak Hospital, İstanbul, Turkey
| | - Özkan Alan
- Medical Oncology, Tekirdağ Public Hospital, Tekirdağ, Turkey
| | - Özge Keskin
- Medical Oncology, Selçuk University School of Medicine, Konya, Turkey
| | - Erdinç Nayır
- Medical Oncology, VM Medical Park Mersin Hospital, Mersin, Turkey
| | - Özgür Tanrıverdi
- Medical Oncology, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey
| | - Tuğba Yavuzşen
- Medical Oncology, Dokuz Eylül University School of Medicine, İzmir, Turkey
| | | | - Öztürk Ateş
- Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Hasan Şenol Coşkun
- Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Serdar Turhal
- Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey
| | - Filiz Çay Şenler
- Medical Oncology, Ankara University School of Medicine, Ankara, Turkey
| |
Collapse
|
7
|
Nikerel IE, Ateş Ö, Öner ET. Effect of bioprocess conditions on growth and alkaline protease production by halotolerant Bacillus licheniformis BA17. APPL BIOCHEM MICRO+ 2008. [DOI: 10.1134/s0003683808050062] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|